US EditionHundreds of Cystic Fibrosis Patients Become Eligible for ‘Life-Changing’ Therapy
ENGLAND, UNITED KINGDOM, JUL 15 – NICE's final draft guidance on Alyftrek aims to expand treatment options for cystic fibrosis patients, with NHS planning rollout after publication, officials said.
4 Articles
4 Articles
Evening Standard
perspectivemedia.comHundreds of cystic fibrosis patients become eligible for ‘life-changing’ therapy
Some people with the rarest forms of the disease have been unable to access the latest medicines.
expert reaction to NICE final draft guidance and NHS rollout of Alyftrek for children and adults with some forms of cystic fibrosis
Scientists comment on NICE final draft guidance and the NHS rollout of Alyftrek for Cystic Fibrosis. David Ramsden, Cystic Fibrosis Trust Chief Executive, said: “Today’s announcements are a positive step in the journey to better treatments for more people with cystic fibrosis – a lifelong, life-limiting condition without a cure. It’s thanks to the incredible hard work and support of the CF community and everyone we work with that modulator dru…
NHS England » NHS to roll-out new ‘triple combination’ therapy for hundreds of children and adults with cystic fibrosis
Hundreds of children and adults with rare forms of cystic fibrosis in England will be able to access “life-changing” new ‘triple-combination’ therapy for the very first time, the NHS has announced. Vanzacaftor–tezacaftor–deutivacaftor (Alyftrek®), is the latest in a new generation of therapies to be made available on the NHS that help treat the underlying cause […]
Coverage Details
Bias Distribution
- 50% of the sources lean Left, 50% of the sources are Center
To view factuality data please Upgrade to Premium
